Alastair J.J. Wood, M.B Ch.B.

Dr. Wood received his medical degree from St Andrew’s University and Dundee Medical School in Scotland. He joined the Faculty at Vanderbilt University School of Medicine in 1978 where he became tenured Professor of both Medicine and Pharmacology and Attending Physician at Vanderbilt Medical School. He was Assistant Vice Chancellor for Clinical Research (1999-2004), and Associate Dean, Vanderbilt Medical School (2004-2006) before being appointed Emeritus Professor of Medicine and Emeritus Professor of Pharmacology in 2006. His current academic appointments are Professor of Medicine and Professor of Pharmacology at Weill Cornell Medical College, New York. He is Managing Director of Symphony Capital LLC, a New York based Private Equity Company managing over $300 million dedicated to investments in the clinical development of novel biopharmaceutical products.

Dr. Wood is a member of many societies and has received numerous honors, notably election to membership of The National Academy of Sciences’ Institute of Medicine, The American Association of Physicians (AAP), The American Society for Clinical Investigation (ASCI), Honorary Fellow, American Gynecological and Obstetrical Society (AGOS), Fellowship of The American College of Physicians, Fellowship of The Royal College of Physicians of London, and Fellowship of The Royal College of Physicians of Edinburgh. He was the 2005 recipient of the Rawls-Palmer Award in recognition of “Drug investigation that brings the effects of modern drug research to the care of patients” from the American Society for Pharmacology and Therapeutics.

Dr. Wood has served on a number of Editorial Boards. He was a member of The New England Journal of Medicine Editorial Board (2004-2006); he was the Drug Therapy Editor of The New England Journal of Medicine from 1985 to 2004, and is also on the Editorial Board of Clinical Pharmacology and Therapeutics and The Scientist. He has previously served on the Editorial Boards of The British Journal of Clinical Pharmacology and Biopharmaceutics and Drug Disposition. He authored the Chapter in Harrison’s Principles of Internal Medicine on Adverse Drug Reactions from the 9th through the 15th edition.

Dr. Wood was the chairman of the FDA’s Nonprescription Drugs Advisory Committee until 2006, and chaired the 2005 FDA Advisory Committee on Cox-2 inhibitors. He previously served as a member of the Cardiovascular and Renal Advisory Committee of the Food and Drug Administration, and the FDA’s Nonprescription Drugs Advisory Committee. Dr. Wood has also been both a member, and has chaired NIH Study Sections, and has served in a similar capacity for various philanthropic grant-giving bodies. He has served as a director of pharmaceutical companies including Antigenics (AGEN), Symphony Neurodevelopment, and Symphony Evolution. He has also served as a consultant to pharmaceutical companies, investors and academic institutions. He has provided Congressional testimony, and directly interacted with and advised senior White House officials, legislators, and the Secretary of Health on matters related to public health. He is a frequent commentator in the national press on issues related to medicine and pharmaceuticals.

His research interests have been focused on understanding the mechanisms for interindividual variability in drug response, with a particular focus on the molecular genetics of adrenergic receptors, ethnic differences in drug response, vascular response, and the genetics of drug metabolism. His research has been continuously funded by NIH, and has resulted in over 280 articles, reviews and editorials.